Despite the rapid increase in knowledge of the molecular basis for monogenic diseases over the last 10 years, their treatment remains unsatisfactory. The latest edition of a leading monograph on the field summarizes the position as follows: of the 570 conditions analysed in detail, 12% showed a complete response to treatment, 54% some partial benefit, and in 34% there was no response at all. 1 It concludes that the most effective forms of management are symptomatic support, substrate limitation, protein replacement, and a small role for the removal of toxic metabolites via the activation of alternate pathways, bone marrow transplantation, and surgery. Pharmacological approaches were only considered of value in 10% of diseases, or less.
There are, of course, good examples of cases in which a knowledge of the molecular pathology of a monogenic disease has led to either definitive or valuable supportive approaches to treatment.
1 They include the development of the statins or bile-binding resins for lowering cholesterol levels in patients with monogenic hypercholesterolemia, agents for the artificial inhibition of the tyrosine pathway to block the synthesis of toxic metabolites for the management of type 1 hereditary tyrosinemia, and biphosphonate therapy aimed at decreasing the rate of bone turnover in patients with osteogenesis imperfecta. Several inherited metabolic diseases appear to show some response to vitamins, vitamin B 6 for the treatment of homocystinuria or thiamine for the management of maple syrup urine disease, for example.
These therapeutic deficiencies are compounded by the relative paucity of genetic diseases that can be managed by organ transplant, and continued difficulties and frustrations in the field of somatic gene therapy. Approaches that involve selective correction of molecular pathology at the DNA or mRNA level are promising, although formidable problems remain before they can be used in the clinic, particularly delivery. Hence, the case for exploring new pharmacological avenues seems to be stronger than ever.
One of the more novel approaches to the pharmacological management of monogenic disease, not discussed widely in the clinical-genetics literature, is the attempt to reactivate genes that are utilized during fetal development to replace the activity of those which carry deleterious mutations and which are expressed mainly in adult life. While this notion has been investigated for many years in the abnormal hemoglobin field, 2, 3 which encompasses the most common human monogenic diseases, it is only in the last few years that some genuine progress has been made.
The two important families of inherited disorders of hemoglobin, b thalassemia and sickle cell anemia, involve defects in either the synthesis or structure of the b globin chains of adult hemoglobin. In adult life, the main hemoglobin is hemoglobin A, which contains pairs of a and b chains (a 2 b 2 ), while in the latter half of fetal life the main hemoglobin is hemoglobin F, which has pairs of a and g chains (a 2 g 2 ). The switch from g to b chain synthesis occurs late in pregnancy. It has been known for many years that patients with serious forms of b thalassemia or with sickle cell anemia who continue to produce unusually high levels of hemoglobin F, that is g chains, after birth tend to run a milder clinical course. 2, 3 In the case of b thalassemia, this is because the main pathophysiological mechanism is globin chain imbalance with precipitation of excess a chains that damage red cell precursors. In sickle cell anemia, on the other hand, the phenotype results from the abnormal structure of the b globin chain, which leads to intravascular sickling and a variety of subsequent complications. Hemoglobin F production is valuable to b thalassemic patients because it reduces the degree of globin chain imbalance, 2 and to patients with sickle cell anemia because hemoglobin F interferes with the sickling process. 3 Despite a great deal of work, very little is known about the mechanisms involved in regulating the switch from g to b chain synthesis. However, many years ago it was observed that patients recovering from bone marrow depression after chemotherapy for leukemia, or in other states in which the bone marrow was rapidly regenerating, tended to produce more foetal haemoglobin during the period of erythroid expansion. This led to the notion that, by the perturbation of erythropoiesis using cytotoxic agents, it might be possible to augment the amount of fetal hemoglobin produced in sickle cell anemia or b-thalassemia. Along the way, it was also found that babies born of diabetic mothers have higher levels of fetal hemoglobin after birth and that the agent responsible is probably butyrate. Could this observa-tion also be utilized to augment hemogobin F production after birth?
The first agent to be used to reactivate fetal hemoglobin was 5-azacytidine, a demethylating agent. 4 The results were encouraging in that it produced an elevation of fetal hemoglobin in a small number of patients with sickle cell anemia, but the studies were not pursued further because of the potential toxicity of the agent. After encouraging animal studies, hydroxyurea was the next drug to be introduced into human clinical studies. 5 The preliminary results led to a large-scale, multicenter trial of hydroxyurea for sickle cell anemia (MSH), which was finally closed in 1994 after 13 months of observation. The results were promising; there was a reduction in painful crises of about 50% and some evidence for reduction in the frequency of other complications although not, importantly, stroke. 6 This trial was followed by a number of smaller scale studies both in adults and children, the results of which, up to 2001, have been extensively summarized. 3 Very recently, the results of a long-term observational follow-up study of some of the original patients of the MSH trial was published. 7 They suggest that adults who receive hydroxyurea for painful sickle cell episodes appear to have a reduced mortality after 9 years of follow-up. Survival was related to the level of hemoglobin F and the frequency of vaso-occlusive events. Equally promising results have been obtained in a number of smaller scale studies involving children (listed Mentzer. 8 ). There have also been several small-scale studies attempting to treat patients with intermediate forms of b thalassemia with hydroxyurea, but although fetal hemoglobin levels have been raised the overall results have not, hitherto, been very impressive. A recent report of the successful treatment of seven patients with severe b thalassemia in Algeria is more encouraging, 9 but must be viewed with caution until more data of this kind are available.
Experience to date of the use of either arginine butyrate or oral sodium phenylbutyrate to augment fetal hemoglobin production have also been summarized recently. 3 In a few cases of b thalassemia of intermediate severity, there have been spectacular increases in hemoglobin F levels, allowing children to lead a transfusion-free life. 10 Mostly, however, the responses have been less spectacular, both in b thalassemia and sickle cell anemia, although intermittent courses of arginine butyrate have shown some promise in the latter condition. 11 Recently, there has been a re-evaluation of the use of DNA demethylating agents and it has been found that an analogue of 5-azacytidine, 5,aza-2 0 -deoxycytidine (decitabine) shows promise as an inducer of fetal hemoglobin synthesis in patients with sickle cell anemia. 12 Similarly, there has been a resurgence of interest in the possibility of using agents that may ameliorate sickle cell anemia by their effects on the microcirculation. For example, a randomized controlled trial of purified poloxamer 188 has shown a significant decrease in episodes of painful crises, although the effects were small. 13 While these results are encouraging there is still much to be learned about the application of these pharmaceutical agents for the treatment of the b hemoglobinopathies. Particularly in the case of sickle cell anemia, it is still not clear what levels of hemoglobin F are required to produce long-term control of the disease. And with our current state of knowledge, it is also not clear which patients should be treated with hydroxyurea, or, whether over a very long period of administration, there is an increased risk of malignant disease. Do these observations on the reactivation of fetal genes have any implications for other human monogenic diseases? Unfortunately, there is only limited information about variation in genetic pathways during human fetal development. However, there may be other applications. For example, it has been found that utrophin, the fetal homologue of dystrophin, may be able to compensate for the defective action of its adult counterpart; certainly this has been found to be possible in mice with Duchenne muscular dystrophy. 14 Thus this field is clearly well worth further exploration.
The recent successes, albeit limited, in the management of the hemoglobin disorders underline the importance of determining the mechanisms for the remarkable phenotypic heterogeneity of monogenic diseases. In the case of the hemoglobin disorders, this has already led to the concept of reactivation of fetal hemoglobin and, in the future, could well lead to other therapeutic approaches, the development of selective suppression of a chain production as a way of managing b thalassemia for example. The exploration of such experiments of nature will be well worth pursuing in the case of other monogenic diseases; if the severity of their phenotypes can be reduced by genetic or even environmental factors, it may be possible to reproduce these effects pharmacologically.
Although the picture is still far from encouraging, there have been some improvements in the management of monogenic diseases over the last 20 years. At the same time, we have gradually started to gain some understanding of their complexity and why they have such varied phenotypes. 15 Such information will surely help to guide us towards more effective pharmacological approaches to their management in the future.
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